Aeglea BioTherapeutics, Inc. - Special Call Transcript
Greetings, and welcome to the Aeglea BioTherapeutics Clinical Update Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. David Calusdian with Sharon Merrill Associates. Thank you. You may begin.
Hello, and welcome to Aeglea BioTherapeutics Clinical Update Conference Call. After management's prepared remarks, they will be available to take your questions.
Before we begin, please note that today's call may include a number of forward-looking statements, including comments on the company's business strategy, strengths and priorities; the timing, plans and success of clinical trials and related data; the timing of announcements and updates related to clinical trials and related data; the safety, therapeutics benefits and economic value of product candidates; the advancement of technologies and proprietary product candidates; regulatory pathways for development programs; the success of collaborations; the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |